Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 12 - Amyotrophic lateral sclerosis

  • Edited by James E. Barrett, Joseph T. Coyle, Michael Williams
  • Book:
    Translational Neuroscience
    Published online:
    05 July 2012
    Print publication:
    28 June 2012, pp 214-227

  • Summary

    Recent advances in research on schizophrenia have significantly changed the manner in which translational research is being conducted in this field. Although there is a lack of gross morphological change observed in the brains of schizophrenic patients, there is substantial evidence that this disorder is one of impaired synaptic connectivity, which has been observed in numerous humans postmortem as well as in functional and structural brain imaging studies. This chapter outlines the major neuropathological and behavioral abnormalities associated with schizophrenia. It discusses the risk genes most implicated in the pathophysiology of schizophrenia and outlines their roles in regulating aspects of neuroplasticity thought to be perturbed in this disease. The chapter describes the pharmacological and genetic animal models that are being used in translational research. It highlights novel therapeutic targets currently being investigated for treating schizophrenia.